SA/UK ADD Hub

The SA/UK ADD Hub's newly launched website! Visit it now, here --> antimicrobialdrugdiscovery.com Find out all about our Newton Fund AMR Project, the Consortium's news, upcoming events and more! Made possible by @MRCza, @NewtonFund, @The_MRC

Prof Rui Krause - Passing of an ADD Hub Member See here for more ---> antimicrobialdrugdiscovery.com/prof-rui-kraus…

Race Against Resistance: The Life And Death Struggle To Save Antibiotics... youtu.be/5U3k9ruszxI?fe… via @YouTube

I’ve come to @thembauk on Plymouth Hoe for the launch of UK’s 1st Marine Microbiome Centre of Excellence! Imagine all the amazing microbiology to be discovered out there…we’re looking for new #antibiotics in #marinefungi with @sea_bugs @SA_UKADDHub

Sharing the WHO's Science in 5 Podcast. Take a moment to listen to what you need to know when taking #antibiotics 💊. #antimicrobialstewardship youtu.be/AJ0Q1FY__C0

WHO's Science in 5: Microbes are becoming resistant to antibiotics youtu.be/ELRw0jRiJe0 via @YouTube

@NewtonFund It is most exciting that we get to do this research and collaborate with other passionate scientists in the field of #AMR and #NPdrugdiscovery!

A major challenge to combating drug-resistant infections is a lack of new drugs being developed💉 A UK-South Africa research team have set up the @SA_UKADDHub to combat this gap in knowledge. Hear from the research team in the video below 👇

‘I work in the field of natural products produced by fungi’ Introducing Dr Claudio Greco - his current research examines a pathogenic filamentous fungus that has co-evolved with leaf-cutter ants 🍄🐜 bit.ly/3WwdWmO @BBSRC #bioscience #research #fungi

#DYK most cases of #Cdiff occur while you’re taking #antibiotics or not long after you’ve finished? Protect yourself and your loved ones from this life-threatening infection. cdc.gov/cdiff/risk.html #CdiffAwarenessMonth

New @WHO data shows that in 2021, #tuberculosis killed someone roughly every 20 seconds. The number of people falling ill with TB and dying from it increased. While the data is devastating, it is sadly unsurprising. [1/7] who.int/news/item/27-1…

And so the 2022 #H3DSymposium comes to a close aftera hugely stimulating and inspiring conference! Thank you to all who made this opportunity possible to network and engage on the critical topics on #drugdiscovery in Africa, and further broad.

Overcoming infectious diseases is a complex and dynamic issue that require novel approaches, multiple approaches and out-of-the-box thinking to tackle #drugdiscovery in light of the #AMR global health issue.

Roi Avraham of @WeizmannScience considers the interaction between pathogens and host, using a Dynamic Deconvolution approach for single cell RNASeq to analysis the impact of human variation on cell-specific pathogen responses.

"Combination therapies is what we should aim for." Anna Hirsch's research tackles #drugdiscovery invesigating a Patholocker approach as adjunctive therapy to antibiotics for hospital-acquired P. aeruginosa infections. #H3DSymposium

Rolf Miller opens the AMR #drugdiscovery session sharing his lab's work on identifying novel NPs from predatory myxobacteria of soil origin. He uses phylogenetically distant strains from those previously characterized to prioritize novel NP discovery. #H3DSymposium

Following a jam-packed day of #drugdiscovery science, we celebrate the amazing research currently underway in Africa at the #H3DSymposium Conference Dinner with a delicious #proudlysouthafican spread.

Such an interesting and hugely topical discussion raised by @mathewnjoroge - how does genetic variation in African populations affect drug metabolism and deposition, and it's impact on development of resistance or drug toxicity.

"A good assay leads to good analysis, which supports good compound analogue design" for #drugdiscovery of XDR TB. Brendan Cowley @MERCK Sharp and Dohme, discusses improving the efficacy and selectivity of linezolid. #H3DSymposium

Clif Barry of the @NIH challenges us to rethink our understanding of treating TB to sterility - is this achievable, particularly with our existing treatment regimens? This is an important consideration in the journey of #drugdiscovery for this critical infectious disease.

Clif Barry of the @NIH challenges us to rethink our understanding of treating TB to sterility - is this achievable, particularly with our existing treatment regimens? This is an important consideration in the journey of #drugdiscovery for this critical infectious disease.